"safety and efficacy of 1-day and 3-day dosing regimens of azithromycin suspension (New Drug Application 50-710, Pfizer Inc.) for the treatment of otitis media."

Briefing Information

Pfizer, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Presentation [pdf version]

FDA Presentation   [pdf version] [html version] [Word version]

Bibliography  [pdf version] [html version] [Word version] (New 11/16/01)